Mondias Natural Products : Creates New Business Units for Human Health, Agriculture and Functional Beverages

Company to Accelerate Growth Under New Structure

MONTREAL, Jan. 30, 2020 /CNW/ - Mondias Natural Products Inc. (TSXV: NHP) (the "Company" or "Mondias") specializing in evidence-based natural products for the healthcare and bio-agriculture markets today announces that the Company has restructured into business units addressing Human Health, Agriculture, and Functional Beverages. The new structure will better meet growing consumer demand for natural based products that improve or maintain health and prepare the Company for its next phase of growth and expansion. Mondias is dedicated to all-natural ingredients "Made by Nature and Superior by Science".

Mondias Business Units

Mondias Human Health products will continue to sell its Holizen branded products into natural products specialty stores in Quebec. The Company recently launched its natural sleep aid Bazzzics as part of its efforts to enter online retail. The Company also plans on launching nationally under its new brand aanii in concert with wholesalers, digital and in-store retail. The Company has an extensive product pipeline of natural health products across multiple therapeutic areas ready for commercialization.    

Mondias Agriculture products has branded its business unit as Celext Agri-Tech and will aim to commercialize its pipeline of organic bio-stimulants and bio-control agents. The lead commercial stage product CELEXT07 is under a commercial research agreement with a multinational agriculture company as announced in September 2019. The final study report is in preparation and the partners will enter a commercial negotiation process as outlined in the previously signed agreement.

Mondias Functional Beverage products has branded its business unit as SetPoint Beverages and will enter the functional beverages market. Products under evaluation are currently generating sales and revenues in FY2020. 

Mondias CEO Dr. Patrick Frankham stated that "We are advancing positively in validating the efficacy of CELEXT07 and see great value creation in capitalizing on our existing portfolio of IP and the creation of business units responds to changing consumer needs and behaviours. Growing organically, is therefore, very promising but to accelerate value we will continue to identify for the right opportunity". Dr. Frankham also stated that "as we execute our plan, the Company will be adding experienced leadership."

Mondias Target Markets

Natural Products
According to an industry report, the US natural personal care market is expected to exceed US $2B in 2019 and it is expected to exceed US $3B by 2025. In this market the emphasis is on skin, hair, oral, cosmetic and hygienic care products. US consumers for natural products are young adults and middle-aged health seekers from middle to high income earners. These consumers prioritize natural products over traditional pharmaceuticals.   

Biopesticides
The overall biopesticides market is projected to grow from USD $3.0B in 2018 to USD $6.4B by 2023, at a CAGR of 15.99% during the forecast period. The rise in the popularity of biopesticides can be attributed to the environment-friendly nature of these products, as they are completely natural and do not harm the environment. There is increasing support for the deployment of biological solutions as alternatives to chemical pesticides in both organic farming and Integrated Pest Management systems. These biological solutions are more cost-effective than chemical pesticides.

Functional Beverages
The global functional drinks market size is expected to reach USD $93.7B by 2019, according to a new study by Grand View Research, Inc., progressing at a CAGR of 6.1% during the forecast period. As health awareness becomes an increasingly important issue in many countries, consumers may shift from sugary soft drinks to healthier alternatives in the functional drinks segment, boosting market growth. 

About Mondias Natural Products Inc.
Mondias specializes in the commercialization and development of evidence-based botanical products for the healthcare, bio-agriculture and organic markets. The company sells both oral and topical botanical agents to help manage unmet medical needs through its Holizen Laboratories division. Mondias is also developing botanical-based specialty fertilizers for use on household plants, lawns and golf courses and in urban gardens, nurseries and greenhouses, in collaboration with McGill's Faculty of Agricultural and Environmental Sciences.

For more information, visit: www.mondias.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by the use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include the Company's inability to obtain sufficient financing to execute its business plan; competition; regulation; anticipated and unanticipated costs and delays; the success of the Company's research and development strategies; the ability to obtain orphan drug status; the applicability of the discoveries made; the successful and timely completion and uncertainties related to the regulatory approval process; the timing of clinical trials; the timing and outcomes of regulatory or intellectual property decisions; and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this news release, and the Company does not undertake any obligation to publicly update them to reflect new information or subsequent events or otherwise except as required by applicable securities legislation.

SOURCE Mondias Natural Products Inc.

© Canada Newswire, source Canada Newswire English